The amygdala and hippocampus have been implicated consistently in the pathophysiology of posttraumatic stress disorder (PTSD).1,2 While several studies have observed reduced hippocampal volume in PTSD, studies of amygdala volume and PTSD have been mixed.1- 3
In addition to method differences, one reason for these mixed results is that most structural magnetic resonance imaging studies in PTSD have treated PTSD as a homogeneous entity instead of considering how amygdala volume may relate to its heterogeneous phenotypic expression.
Confirmatory factor analytic studies have revealed that PTSD is best represented by 5 symptom clusters: reexperiencing, avoidance, numbing, dysphoric arousal (eg, sleep difficulties), and anxious arousal (eg, hypervigilance).4 To our knowledge, no study has evaluated the relation between amygdala and hippocampal volume and this contemporary model of PTSD. Here, we evaluated these associations in combat veterans.
Forty-eight Iraq/Afghanistan combat veterans participated in this study. Recruitment was conducted to ensure a full dimensional range of DSM-IV PTSD symptoms (ie, including non/minimally symptomatic veterans and equal proportions of veterans with mild, moderate, and severe/extreme symptoms), with 23 veterans (47.9%) meeting diagnostic criteria for combat-related PTSD. Exclusion criteria included psychosis; bipolar disorder; drug abuse or dependence (current or lifetime); alcohol abuse in the past 30 days or alcohol dependence in the past 12 months; moderate and severe traumatic brain injury (ie, loss of consciousness >30 minutes); neurologic disorder (eg, stroke or seizure); learning disability or confirmed diagnosis of attention-deficit/hyperactivity disorder; use of antipsychotics, psychostimulants, or sedatives/hypnotics; antidepressant dose stable less than 30 days; and/or PTSD diagnosis prior to combat exposure. The VA Connecticut Healthcare System Human Subjects Subcommittee and Yale University Human Research Protection Program approved this study. All participants provided written informed consent.
Structural magnetic resonance imaging data were acquired on a Siemens Trio TIM 3T (MPRAGE; voxel size 1 × 1 × 1 mm; repetition time, 2.5 seconds; echo time, 2.77 milliseconds; flip angle, 7°). Blinded to the clinical status, image processing and segmentation were conducted using the fully automated Freesurfer recon-all pipeline (http://surfer.nmr.mgh.harvard.edu).
We computed partial correlations between independent variables and amygdala and hippocampal volumes adjusted for total intracranial volume and entered variables with associations at the P < .05 level into a multivariable linear regression analysis using total intracranial volume as a covariate. To evaluate subscales of the Clinician-Administered PTSD Scale associated with volumes, we conducted a post hoc multivariable linear regression analysis (α = .01). Finally, to evaluate interrelationships among variables related to regional volumes, exploratory path analyses were conducted using Mplus version 7.2 (http://www.statmodel.com).
The Table shows sample characteristics and partial correlation results. After adjustment for intracranial volume, Combat Experiences Scale and total Clinician-Administered PTSD Scale scores were independently associated with right amygdala volume. Multivariable linear regression for right amygdala volume showed adjusted R2 = 0.46 (Combat Experiences Scale: β = −0.27; t = 2.34; P = .02; Clinician-Administered PTSD Scale: β = −0.24; t = 2.10; P = .04). Post hoc analysis revealed that anxious arousal was independently negatively related to right amygdala volume (β = −0.38; t = 3.33; P = .002); no other symptom cluster was significant (β > −0.08; t < 0.53; and P > .59 for all). The best-fitting model in path analyses showed right amygdala volume mediating the relationship between combat exposure and anxious arousal (χ2 = 0.03; P = .87; Bayesian Information Criterion = 921.38; Akaike Information Criterion = 906.41; root mean square error of approximation = 0.00 [0.00-0.20]; Comparative Fit Index = 1.00; Tucker-Lewis Index = 1.00; the other 2 models had χ2 = 3.17 or higher, P = .07 or lower, and higher root mean square error of approximation and lower Comparative Fit Index and Tucker-Lewis Index values, which indicate worse fit). The Figure shows standardized coefficients of the best-fitting model.
The values represent standardized β coefficients. The solid lines represent significant associations; dotted line, nonsignificant association. Right amygdala volume was additionally regressed on total intracranial volume in all path models. Association between combat exposure severity and anxious arousal was significant when right amygdala volume was excluded from the model (β = 0.31; t = 2.22; P = .03). The 95% CI for the association between combat exposure severity and anxious arousal when right amygdala volume was excluded from the model was −0.16 to 0.43; for combat exposure severity and right amygdala volume, −0.10 to −0.52; and for right amygdala volume and anxious arousal, −0.17 to −0.67.aP < .01.bP < .001.
This study suggests that reduced right amygdala volume is most strongly associated with anxious arousal symptoms in combat veterans. This finding is consistent with experimental studies linking reduced amygdala volume to stress-evoked hyperresponsiveness.5,6 Right amygdala volume also fully mediated the relation between combat exposure severity and anxious arousal, suggesting that increased combat exposure may contribute to reduced amygdala volume, which in turn is associated with increased anxious arousal.
While this study was limited by the cross-sectional design and relatively small and predominantly male sample, the results underscore the potential utility of a dimensional approach to evaluating neurobiological factors associated with PTSD. Such an approach may be useful in informing etiologic models, as well as prevention and treatment approaches for this debilitating disorder.
Corresponding Author: Robert H. Pietrzak, PhD, MPH, US Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, VA Connecticut Healthcare System, 950 Campbell Ave, 151E, West Haven, CT 06516 (firstname.lastname@example.org).
Published Online: February 18, 2015. doi:10.1001/jamapsychiatry.2014.2470.
Author Contributions: Dr Pietrzak had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Pietrzak and Averill contributed equally.
Study concept and design: Pietrzak, Neumeister, Krystal, Harpaz-Rotem.
Acquisition, analysis, or interpretation of data: Pietrzak, Averill, Abdallah, Neumeister, Levy, Harpaz-Rotem.
Drafting of the manuscript: Pietrzak.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Pietrzak, Averill.
Obtained funding: Neumeister, Krystal, Harpaz-Rotem.
Administrative, technical, or material support: Pietrzak.
Study supervision: Abdallah, Neumeister, Krystal, Levy.
Conflict of Interest Disclosures: Dr Pietrzak is a scientific consultant to Cogstate Ltd. Dr Abdallah has received consultation fees from Genentech. Dr Krystal consults for several pharmaceutical and biotechnology companies. No other disclosures were reported.
Funding/Support: Preparation of this study was supported in part by the Clinical Neurosciences Division of the US Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, grant K23 MH-101498 from the National Institutes of Health (Dr Abdallah), and a private donation.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of sponsoring organizations, agencies, or the US government.
Pietrzak RH, Averill LA, Abdallah CG, Neumeister A, Krystal JH, Levy I, Harpaz-Rotem I. Amygdala-Hippocampal Volume and the Phenotypic Heterogeneity of Posttraumatic Stress DisorderA Cross-Sectional Study. JAMA Psychiatry. 2015;72(4):396-398. doi:10.1001/jamapsychiatry.2014.2470